Transcriptional regulator pca r, mutants thereof and engineered bacteria thereof
By mutating the transcriptional regulator PcaR with amino acids, an engineered bacterium was constructed, which solved the problem of insufficient amino acid synthesis and extracellular accumulation capacity in the existing technology, and achieved a significant improvement in threonine yield and conversion rate.
Patent Information
- Application Number
- CN202411801712.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-09
- Publication Date
- 2026-06-09
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This invention relates to the field of genetic engineering technology, and in particular to the transcriptional regulatory factor PcaR, its mutants and engineered bacteria. Background Technology
[0002] Microbial cells possess complex transcriptional regulatory networks and mechanisms, with transcription factors being crucial elements in regulating gene transcription. As an important industrial microorganism, *Corynebacterium glutamicum* has identified several transcription factors that regulate the synthesis of biobased chemicals such as amino acids. However, a large number of transcription factors with unknown functions remain to be discovered and studied. The discovery of transcription factors that regulate amino acid synthesis and extracellular accumulation, along with their mutants, can provide new targets for amino acid strain modification, thus promoting improved strain productivity. Summary of the Invention
[0003] This invention provides the transcriptional regulatory factor PcaR, its mutants, and its engineered strains.
[0004] This invention unexpectedly discovered that the transcription factor PcaR plays a regulatory role in the synthesis and extracellular accumulation of amino acids such as threonine, and developed a mutant transcription factor PcaR that can enhance the production capacity of amino acids (especially threonine; unless otherwise specified in this invention, all amino acids refer to L-amino acids). Based on this mutant transcription factor PcaR, this invention constructed engineered bacteria. Verification showed that the introduction of this mutant transcription factor PcaR significantly improved the yield and conversion rate of amino acids (especially threonine) in the engineered bacteria.
[0005] Specifically, the present invention provides the following technical solutions.
[0006] In a first aspect, the present invention provides an engineered bacterium that expresses a mutated transcriptional regulatory factor or contains a nucleic acid molecule encoding the mutated transcriptional regulatory factor; The mutated transcriptional regulator, compared with the wild-type transcriptional regulator PcaR of Corynebacterium glutamicum, contains a mutation at amino acid position 193, which is either threonine or serine.
[0007] Preferably, the mutated transcription factor contains a mutation at position 193, where alanine is mutated to threonine (A193T) or serine (A193S), compared to the wild-type transcription factor PcaR of Corynebacterium glutamicum; wherein the wild-type transcription factor PcaR of Corynebacterium glutamicum has an amino acid sequence as shown in SEQ ID NO. 5, 7 or 9.
[0008] Preferably, the amino acid sequence of the mutated transcriptional regulator is any one of the following (1)-(3): (1) The amino acid sequence obtained by mutating alanine at position 193 of the sequence shown in SEQ ID NO.5 to threonine or serine; (2) The amino acid sequence obtained by mutating alanine at position 193 of the sequence shown in SEQ ID NO.7 to threonine or serine; (3) The amino acid sequence obtained by mutating alanine at position 193 of the sequence shown in SEQ ID NO.9 to threonine or serine.
[0009] For example, the mutant in (1) above has an amino acid sequence as shown in SEQ ID NO.1 or 2.
[0010] Preferably, the engineered bacteria are Corynebacterium or Escherichia. The Corynebacterium species is preferably Corynebacterium glutamicum; the Escherichia species is preferably Escherichia coli.
[0011] The engineered bacteria described above are able to accumulate amino acids, and their threonine production and / or conversion rate are increased by expressing mutated transcription factors or containing nucleic acid molecules encoding said mutated transcription factors.
[0012] In this invention, the conversion rate refers to the ratio of substrate to threonine. For example, when glucose is used as the substrate, the conversion rate is the glucose-acid conversion rate.
[0013] Preferably, the original transcriptional regulatory factor PcaR of the engineered bacteria is not expressed or is inactivated.
[0014] Preferably, the original transcription factor PcaR of the engineered bacteria is mutated into the mutated transcription factor described above.
[0015] The present invention does not impose any particular restrictions on the starting strain of the engineered bacteria; it can be any bacterium, preferably a Corynebacterium or Escherichia coli. Preferably, the starting bacteria can be any strain capable of synthesizing and accumulating amino acids (especially threonine), including but not limited to wild-type strains, amino acid-producing strains obtained through genetic engineering or mutagenesis breeding, etc.
[0016] The engineered bacteria described above can be obtained by mutating the original transcription factor PcaR encoding gene in the starting strain so that it encodes the mutated transcription factor.
[0017] As a preferred embodiment of the present invention, a *Corynebacterium glutamicum* engineered strain is provided, which expresses the mutated transcriptional regulatory factor described above or contains a nucleic acid molecule encoding the mutated transcriptional regulatory factor. The amino acid yield (especially threonine) and / or conversion rate of the engineered strain are significantly improved.
[0018] In some specific embodiments of the present invention, a Corynebacterium glutamicum engineered strain is provided, wherein the gene sequence encoding the transcriptional regulatory factor PcaR is mutated, resulting in the protein it encodes being mutated into the aforementioned mutated transcriptional regulatory factor.
[0019] The originating strain of the engineered Corynebacterium glutamicum is not particularly limited in principle in this invention and can be any Corynebacterium glutamicum. Preferably, it is a Corynebacterium glutamicum capable of synthesizing and accumulating amino acids (especially threonine), including but not limited to wild-type Corynebacterium glutamicum, and amino acid-producing Corynebacterium glutamicum obtained through genetic engineering or mutagenesis breeding.
[0020] In some specific embodiments of the present invention, the starting strain is wild-type Corynebacterium glutamicum, and the wild-type Corynebacterium glutamicum is ATCC 13032, ATCC 13869 or ATCC 14067.
[0021] In some specific embodiments of the present invention, the starting strain is a threonine-producing Corynebacterium glutamicum genetically engineered bacterium, which, compared with wild-type Corynebacterium glutamicum, has an enhanced threonine-terminal synthesis pathway and relieves feedback inhibition on key genes at the threonine terminus.
[0022] Optionally, the genetically engineered bacteria comprises one or more of the following modifications: (1) Expression or overexpression of the thrABC gene; (2) Mutate the lysC gene so that the 311th amino acid of its encoded protein is changed from T to I (lysC). T311I ); (3) Mutate the hom gene so that the 378th amino acid of its encoded protein changes from G to E (hom G378E ).
[0023] In (1) above, the expression refers to the expression of a heterologous (preferably from Escherichia coli) thrABC gene; the overexpression refers to the enhancement of the expression of the endogenous thrABC gene.
[0024] It should be noted that the above modifications are merely examples, intended to endow the starting strain with a certain threonine production capacity, and do not constitute a restriction on the genetic background of the starting strain. Those skilled in the art can choose any strain with threonine synthesis and accumulation capacity as the starting strain.
[0025] This invention constructed engineered strains expressing the mutated transcriptional regulatory factor using Corynebacterium glutamicum with different genetic backgrounds as starting strains. Verification showed that these engineered strains significantly improved threonine production and conversion rate. Therefore, the mutated transcriptional regulatory factor of this invention enhances the threonine production capacity of the strains independently of the genetic background of the strains; the genetic modifications to the strains are solely to enable them to produce a certain amount of threonine. Thus, the mutated transcriptional regulatory factor of this invention has universal applicability to starting strains capable of synthesizing and accumulating threonine. Introducing this mutated transcriptional regulatory factor into other threonine-producing strains can effectively promote the increase of threonine production and / or conversion rate.
[0026] Secondly, the present invention provides the application of the engineered bacteria described above in the production of amino acids or their derivatives.
[0027] Preferably, the amino acid is threonine.
[0028] In this invention, the derivatives of the amino acid can be compounds synthesized using the amino acid as a precursor or intermediate. For threonine, its derivatives include isoleucine.
[0029] Thirdly, the present invention provides a method for producing amino acids or their derivatives, the method comprising: culturing the engineered bacteria described above, and collecting the amino acids or their derivatives from the culture.
[0030] Preferably, the method includes: seed culture of the engineered bacteria to obtain seed liquid, inoculating the seed liquid into a fermentation medium for fermentation culture to obtain fermentation broth, and separating and extracting the amino acid or its derivative from the fermentation broth.
[0031] Preferably, the amino acid is threonine.
[0032] Fourthly, the present invention provides a method for increasing the threonine yield and / or conversion rate of a strain, the method comprising: modifying the strain to express the mutated transcriptional regulatory factor described above.
[0033] Preferably, the method includes: using genetic engineering methods to mutate the original transcriptional regulatory factor PcaR of the strain, so that its encoded protein is mutated into the mutated transcriptional regulatory factor described above.
[0034] Fifthly, the present invention provides a mutated transcriptional regulator, which, compared with the wild-type transcriptional regulator PcaR of Corynebacterium glutamicum, contains a mutation in the 193rd amino acid, which is a mutation of threonine or serine.
[0035] Verification showed that mutating the 193rd amino acid of the transcriptional regulator PcaR to threonine or serine can effectively promote the synthesis and extracellular accumulation of threonine, significantly increasing the yield and conversion rate of threonine.
[0036] Preferably, the mutated transcription factor contains a mutation at position 193, where alanine is mutated to threonine or serine, compared to the wild-type transcription factor PcaR of Corynebacterium glutamicum; wherein the wild-type transcription factor PcaR of Corynebacterium glutamicum has an amino acid sequence as shown in SEQ ID NO. 5, 7 or 9.
[0037] As a preferred embodiment of the present invention, the amino acid sequence of the mutated transcription regulatory factor is any one of the following (1)-(3): (1) The amino acid sequence obtained by mutating alanine at position 193 of the sequence shown in SEQ ID NO.5 to threonine or serine; (2) The amino acid sequence obtained by mutating alanine at position 193 of the sequence shown in SEQ ID NO.7 to threonine or serine; (3) The amino acid sequence obtained by mutating alanine at position 193 of the sequence shown in SEQ ID NO.9 to threonine or serine.
[0038] For example, the mutant in (1) above has an amino acid sequence as shown in SEQ ID NO.1 or 2.
[0039] This invention experimentally verified that the mutated transcriptional regulatory factors shown in (1)-(3) above can significantly improve the threonine production capacity of the strain. Those skilled in the art will understand that adding one or more amino acid residues that do not affect protein function to the N-terminus and / or C-terminus of the amino acid sequences shown in (1)-(3) above will not have a significant impact on the function of the mutated transcriptional regulatory factor. For example, adding amino acid residues such as protein tags, signal peptides, and linker peptides to the N-terminus and / or C-terminus of the amino acid sequences shown in (1)-(3) above can still achieve the above-mentioned effect of improving threonine production capacity, and therefore is also within the scope of protection of this invention.
[0040] Sixthly, the present invention provides biomaterials, said biomaterials comprising any one of the following: (1) Nucleic acid molecules encoding the transcriptional regulatory factors of the mutations described above; (2) An expression cassette containing the nucleic acid molecule described in (1); (3) A vector comprising the nucleic acid molecule described in (1) or the expression cassette described in (2); (4) A host cell containing the nucleic acid molecule described in (1) or the expression cassette described in (2) or the vector described in (3).
[0041] For the nucleic acid molecule described in (1) above, based on the amino acid sequence of the mutated transcription regulatory factor provided above, those skilled in the art can obtain the nucleotide sequence of the nucleic acid molecule encoding the mutated transcription regulatory factor. Due to the degeneracy of codons, the nucleotide sequence of a nucleic acid molecule encoding a mutated transcription regulatory factor is not unique, and all nucleic acid molecules capable of encoding the mutated transcription regulatory factor are within the scope of protection of this invention.
[0042] In some specific embodiments of the present invention, the nucleotide sequence of the nucleic acid molecule is as shown in SEQ ID NO.3 or 4.
[0043] The expression cassette in (2) above can be a recombinant nucleic acid molecule obtained by operably linking the nucleic acid molecule with transcriptional and / or translational regulatory elements.
[0044] The vectors mentioned in (3) above include, but are not limited to, plasmid vectors, viral vectors, and transposons.
[0045] The host cell in (4) above is any cell capable of carrying the above-mentioned nucleic acid molecules or expressing the mutated transcriptional regulatory factors, including microbial cells, preferably Escherichia coli, Corynebacterium, or Bacillus.
[0046] In a seventh aspect, the present invention provides any of the following applications of the transcriptional regulatory factor PcaR or the mutated transcriptional regulatory factor described above, or the biological material thereof: (1) Application in regulating the production capacity of bacterial amino acids or their derivatives; (2) Application in the construction of bacteria for the production of amino acids or their derivatives; (3) Applications in the production of amino acids or their derivatives; (4) Application in increasing the yield and / or conversion rate of bacterial amino acids or their derivatives; (5) Application as a marker in screening bacteria for the production of amino acids.
[0047] In the above applications, the transcriptional regulatory factor PcaR preferably has an amino acid sequence as shown in SEQ ID NO. 5, 7 or 9.
[0048] In the above applications, the amino acid is preferably threonine.
[0049] In the above applications, the bacteria are preferably Corynebacterium or Escherichia. Specifically, the Corynebacterium species is preferably Corynebacterium glutamicum; and the Escherichia species is preferably Escherichia coli.
[0050] Eighth aspect, a method for regulating the threonine production capacity of bacteria, the method comprising: regulating the gene of the bacterial transcriptional regulatory factor PcaR.
[0051] This invention discovers that the threonine production capacity of a strain can be regulated by controlling the gene encoding the transcriptional regulatory factor PcaR. The transcriptional regulatory factor PcaR can be used as a target for modification to construct amino acid-producing bacteria such as threonine.
[0052] The above-mentioned regulation can be either at the expression level or at the enzyme activity level. Regulating the transcription factor PcaR at either the expression or enzyme activity level can significantly increase the threonine yield and / or conversion rate of the strain.
[0053] The transcription factor PcaR can be regulated at the expression level or enzyme activity level by mutating the gene encoding PcaR.
[0054] Preferably, the bacteria are Corynebacterium or Escherichia. The Corynebacterium species is preferably Corynebacterium glutamicum; the Escherichia species is preferably Escherichia coli.
[0055] Preferably, the amino acid is threonine.
[0056] In this invention, the production capacity refers to the ability of bacteria to synthesize and / or accumulate amino acids, including but not limited to the yield, conversion rate, and production intensity of amino acids.
[0057] Preferably, the transcriptional regulatory factor PcaR is the transcriptional regulatory factor PcaR of Corynebacterium glutamicum. The transcriptional regulatory factor PcaR has the NCBI number NCgl2308 in ATCC13032, and its encoding gene nucleotide sequence is shown in SEQ ID NO. 6, and its encoding protein sequence is shown in SEQ ID NO. 5; in ATCC13869, it has the NCBI number BBD29_11405, and its encoding gene nucleotide sequence is shown in SEQ ID NO. 8, and its encoding protein sequence is shown in SEQ ID NO. 7; in ATCC14067, it has the NCBI number CEY17_11735, and its encoding gene nucleotide sequence is shown in SEQ ID NO. 10, and its encoding protein sequence is shown in SEQ ID NO. 9.
[0058] The beneficial effects of this invention include at least the following: This invention discovers that the transcriptional regulatory factor PcaR has the function of regulating the production of amino acids such as threonine, and can be used as a target for metabolic modification of amino acid-producing strains; This invention provides a mutant of the transcriptional regulatory factor PcaR, which can significantly improve the production capacity of amino acids such as threonine in bacteria; The engineered bacteria constructed based on this mutant have significantly improved threonine yield and conversion rate, and have good application prospects in the field of amino acid fermentation. Detailed Implementation
[0059] This invention provides the application of the transcriptional regulatory factor PcaR in regulating the production capacity of bacterial amino acids or their derivatives. The transcriptional regulatory factor PcaR can serve as a novel metabolic modification target for the construction of amino acid-producing bacterial strains.
[0060] This invention also provides a mutated transcription regulator whose amino acid sequence is obtained by mutating alanine at position 193 of the amino acid sequence shown in SEQ ID NO. 5, 7 or 9 to threonine (named PcaR respectively). A193T -1, PcaR A193T -2, PcaR A193T -3) or serine (named PcaR respectively) A193S -1, PcaR A193S -2, PcaR A193S -3) obtained.
[0061] The present invention also provides an engineered strain of Corynebacterium glutamicum that expresses the above-described mutated transcriptional regulatory factors.
[0062] Corynebacterium glutamicum carrying the above-mentioned mutations in transcriptional regulatory factors can be used to produce amino acids, especially threonine, with higher production efficiency.
[0063] Preferably, the recombinant Corynebacterium glutamicum is obtained by mutating the gene encoding the original transcriptional regulatory factor PcaR of the starting strain so that it encodes the mutated transcriptional regulatory factor.
[0064] Preferably, the starting strain is obtained by introducing the thrABC gene of the threonine terminal synthesis pathway from Escherichia coli into Corynebacterium glutamicum and relieving the feedback inhibition of the key genes lysC and hom for threonine synthesis.
[0065] As an example, this invention uses three Corynebacterium glutamicum model strains as test subjects. The thrABC gene from the threonine terminal synthesis pathway of Escherichia coli was introduced using genetic engineering methods, and the feedback inhibition of the key threonine synthesis genes lysC and hom was relieved, resulting in three threonine-producing strains, named SMCT301, SMCT302, and SMCT303, which, along with the three Corynebacterium glutamicum model strains, served as starting strains. Based on the above six starting strains, the coding sequence of the original transcriptional regulator PcaR gene in the starting strains was mutated using genetic engineering methods, causing a mutation at amino acid position 193 of its protein sequence, changing alanine to threonine or serine, thereby obtaining engineered Corynebacterium glutamicum. Fermentation experiments verified that, compared with the starting strains, the threonine yield and conversion rate of the engineered Corynebacterium glutamicum were significantly improved.
[0066] The *Corynebacterium glutamicum* strains ATCC 13032, ATCC 13869, and ATCC 14067 used in this invention are all model strains of *Corynebacterium glutamicum*, which are publicly available. Their genome sequences are publicly available and can be found on the NCBI website. *Escherichia coli* MG1655 is a model strain of *Escherichia coli*, which is also publicly available. Its genome sequence is publicly available and can be found on the NCBI website.
[0067] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions of this invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of this invention, not all embodiments. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.
[0068] In the following examples, the key gene lysC for threonine synthesis encodes aspartate kinase, and hom encodes homoserine dehydrogenase. Point mutations are used to remove the feedback inhibition of threonine on this enzyme. The threonine terminal synthesis pathway is achieved by referencing the thrABC operon from E. coli MG1655, where thrA encodes a bifunctional enzyme, namely aspartate kinase and homoserine dehydrogenase, thrB encodes homoserine kinase, and thrC encodes threonine synthase. Among them, lysC has the NCBI number NCgl0247 in Corynebacterium glutamicum ATCC13032, BBD29_01500 in ATCC13869, and CEY17_01500 in ATCC14067; hom has the NCBI number NCgl1136 in ATCC13032, BBD29_06325 in ATCC13869, and CEY17_06455 in ATCC14067; thrA, thrB, and thrC have the NCBI numbers IEU92_RS00010, IEU92_RS00015, and IEU92_RS00020, respectively.
[0069] In the following examples, the encoding gene of the wild-type transcription factor (PcaR) is NCBI number NCgl2308 in ATCC13032, and its nucleotide sequence is shown in SEQ ID NO. 6, while its protein sequence is shown in SEQ ID NO. 5. The amino acid sequence of the mutant obtained based on this wild-type PcaR is shown in SEQ ID NO. 1 or 2, and its encoding gene sequence is shown in SEQ ID NO. 3 or 4. The NCBI number in ATCC13869 is BBD29_11405, and its encoding gene nucleotide sequence is shown in SEQ ID NO. 8, while its protein sequence is shown in SEQ ID NO. 7. The NCBI number in ATCC14067 is CEY17_11735, and its encoding gene nucleotide sequence is shown in SEQ ID NO. 10, while its protein sequence is shown in SEQ ID NO. 9. The encoding gene of the mutant transcription factor can be obtained by fusion PCR or by whole-genome synthesis by a gene synthesis company. The encoding gene of the mutant transcription factor of the present invention was obtained by whole-genome synthesis by a third-party gene synthesis company.
[0070] In the following embodiments, unless specific techniques or conditions are specified, they were performed in accordance with the techniques or conditions described in the literature in this field, or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased through legitimate channels.
[0071] The plasmid pk18mobsacB-speC used in the following examples was prepared by genetically engineering the kanamycin resistance gene of the pK18mobsacB plasmid (GenBank: FJ1287239.1; available for purchase from public channels) to replace it with the spectinomycin resistance gene.
[0072] The primer sequence information used in the following examples is shown in Table 1.
[0073] Table 1 Primer sequence information
[0074] Example 1: Construction of an engineered plasmid carrying the thrABC gene, a threonine-terminal metabolic pathway. Using the whole genome of *Escherichia coli* MG1655 as a template, PCR amplification was performed using the thrABC-f / thrABC-r primer pair. The PCR product was purified by gel electrophoresis and gel extraction. The PCR product was a sequence fragment carrying the thrABC gene, a metabolic pathway gene with a threonine terminus.
[0075] The plasmid vector used was pVWEx1 (GenBank: MF034723.1; purchased from public sources). This vector was linearized by PCR amplification using the pVWEx1-f / pVWEx1-r primer pair. The PCR products were purified by gel electrophoresis and gel extraction for later use.
[0076] The sequence fragment carrying thrABC and the linearized vector were circularized and assembled. Assembly was performed using a single-fragment assembly kit from Novizan. Specific instructions for the kit can be found in the kit's manual. Transformants were screened on kanamycin plates, and the resulting transformants were cultured overnight in LB liquid medium. Plasmids were extracted the following day and sequenced. The correctly sequenced plasmid was named pVWEx1-thrABC.
[0077] Example 2: Carrying the key gene lysC for threonine synthesis T311I Construction of 3 engineered plasmids lysC of ATCC13032 synthesized from the whole genome T311I Using the sequence as a template, PCR amplification was performed with the lysC-f-1 / lysC-r-1 primer pair. The PCR product was purified by gel electrophoresis and gel extraction. The PCR product was a lysC sequence carrying the homologous recombination sequence of the Corynebacterium glutamicum model strain ATCC13032. T311I (It encodes a mutant of the lysC protein). The lysC protein of ATCC13869 was synthesized using the whole genome. T311IUsing the gene sequence as a template, PCR amplification was performed with the lysC-f-2 / lysC-r-2 primer pair. The PCR product was purified by gel electrophoresis and gel extraction. The PCR product was a lysC gene carrying the homologous recombination sequence of the Corynebacterium glutamicum model strain ATCC13869. T311I (It encodes a mutant of the lysC protein). The lysC protein of ATCC14067 was synthesized using the whole genome. T311I Using the gene sequence as a template, PCR amplification was performed with the lysC-f-3 / lysC-r-3 primer pair. The PCR product was purified by gel electrophoresis and gel extraction. The PCR product was lysC carrying the homologous recombination sequence of the Corynebacterium glutamicum model strain ATCC14067. T311I (It encodes a mutant of the lysC protein); all mutants differ from the wild-type lysC protein in that the mutation at position 311 is a change from threonine to isoleucine.
[0078] The plasmid vector used was pK18mobsacB-speC, which had been pre-linearized by double enzyme digestion. The restriction endonucleases were EcoRI and HindIII from NEB. The vector was purified by enzyme digestion and then used for later use.
[0079] The lysCs carrying the homologous recombination sequences ATCC13032, ATCC13869, and ATCC14067 were respectively... T311I The linearized vector was then circularized and assembled. Assembly was performed using a single-fragment assembly kit from Novizan. Specific instructions were provided in the kit's manual. Transformants were screened on spectinomycin-resistant plates. The obtained transformants were cultured overnight in LB liquid medium, and plasmids were extracted the following day for sequencing analysis. LysC vectors correctly sequenced, carrying homologous recombination sequences of ATCC13032, ATCC13869, and ATCC14067, respectively. T311I The plasmid was named pK18mobsacB-speC-lysC T311I -1、pK18mobsacB-speC-lysC T311I -2 and pK18mob sacB-speC-lysC T311I -3 quality.
[0080] Example 3: Carrying the key gene hom for threonine synthesis G378E Construction of 3 engineered plasmids homogeneous synthesis of ATCC13032 G378EUsing the sequence as a template, PCR amplification was performed with the hom-f-1 / hom-r-1 primer pair. The PCR product was purified by gel electrophoresis and gel extraction. The PCR product was a hom-f-1 primer carrying the homologous recombination sequence of the Corynebacterium glutamicum model strain ATCC13032. G378E (It encodes a mutant of the hom protein). The hom protein of ATCC13869 was synthesized using the whole genome. G378E Using the sequence as a template, PCR amplification was performed with the hom-f-2 / hom-r-2 primer pair. The PCR product was purified by gel electrophoresis and gel extraction. The PCR product was a hom-f-2 primer carrying the homologous recombination sequence of the Corynebacterium glutamicum model strain ATCC13869. G378E (It encodes a mutant of the hom protein). The hom protein of ATCC14067 was synthesized using the whole genome. G378E Using the sequence as a template, PCR amplification was performed with the hom-f-3 / hom-r-3 primer pair. The PCR product was purified by gel electrophoresis and gel extraction. The PCR product was a hom-f-3 primer carrying the homologous recombination sequence of the Corynebacterium glutamicum model strain ATCC14067. G378E (It encodes a mutant hom protein). All mutants differ from the wild-type hom protein in that the mutation at position 378 is a change from G to E.
[0081] The plasmid vector used was pK18mobsacB-speC, which had been pre-linearized by double enzyme digestion. The restriction endonucleases were EcoRI and HindIII from NEB. The vector was purified by enzyme digestion and then used for later use.
[0082] The above-mentioned homogeneous recombination sequences carrying ATCC13032, ATCC13869 and ATCC14067 were respectively... G378E The linearized vector was then circularized and assembled. Assembly was performed using the Novizan single-fragment assembly kit. Specific instructions were provided in the kit's manual. Transformants were screened on spectinomycin-resistant plates. The obtained transformants were cultured overnight in LB liquid medium, and plasmids were extracted the following day for sequencing analysis. Homologous recombination sequences carrying ATCC13032, ATCC13869, and ATCC14067 were correctly sequenced. G378E The plasmid was named pK18mobsacB-speC-hom G378E -1、pK18mobsacB-speC-hom G378E -2 and pK18mob sacB-speC-hom G378E -3.
[0083] Example 4 Construction of engineered plasmids carrying transcription factor mutants The transcription factor pcaR mutants, synthesized from the whole genome (the amino acid sequences of the mutants are obtained by mutating alanine at position 193 of the amino acid sequence shown in SEQ ID NO. 5, 7, or 9 to threonine respectively), were named PcaR. A193T -1, PcaR A193T -2, PcaR A193T -3) or serine (named PcaR respectively) A193S -1, PcaR A193S -2, PcaR A193S -3) We obtained two mutants, PcaR, by mutating alanine at position 193 of the sequence shown in SEQ ID NO.5 to threonine and serine. A193T -1 and PcaR A193S Using the gene sequences encoding pcaR-1 (as shown in SEQ ID NO. 3 and 4, respectively) as templates, PCR amplification was performed using the pcaR-f / pcaR-r primer pair. The PCR products were purified by gel electrophoresis and gel extraction. The PCR products were pcaR-f primers carrying homologous recombination sequences. A193T or pcaR A193S .
[0084] The plasmid vector used was pK18mobsacB-speC, which had been pre-linearized by double enzyme digestion. The restriction endonucleases were EcoRI and HindIII from NEB. The vector was purified by enzyme digestion and then used for later use.
[0085] The above-mentioned PcaR carrying homologous recombination sequences were respectively... A193T -1, PcaR A193T -2, PcaR A193T -3, PcaR A193S -1, PcaR A193S -2, PcaR A193S -3 gene and linearized vector were circularized and assembled. Assembly was performed using a single-fragment assembly kit from Novizan. Specific instructions for the kit were provided. Transformants were screened on spectinomycin resistance plates, and the obtained transformants were cultured overnight in LB liquid medium. Plasmids were extracted the following day and sequenced. The correctly sequenced plasmid was named pK18mobsacB-speC-pcaR. A193T -1、pK18mobsacB-speC-pcaR A193T -2、pK18mobsacB-speC-pcaR A193T -3 and pK18mobsacB-speC-pcaR A193S -1、pK18mobsacB-speC-pcaR A193S-2、pK18mobsacB-speC-pcaR A193S -3.
[0086] Example 5: Introduction of the thrABC gene into the Corynebacterium glutamicum model strains ATCC 13032, ATCC 13869, and ATCC 14067. Competent cells of the C. glutamicum model strains ATCC 13032, ATCC 13869, and ATCC 14067 were prepared and exogenous genes were expressed according to the method described in the C. glutamicum Handbook (Charpter 23).
[0087] The expression plasmid pVWEx1-thrABC was transformed into ATCC 13032, ATCC 13869, and ATCC 14067 competent cells using electroporation, and transformants were screened on BHI selective medium containing 25 mg / L kanamycin. The screened transformants were cultured overnight in BHI liquid medium containing 25 mg / L kanamycin at 30°C with shaking at 200 rpm. The target sequence was amplified by PCR, and nucleotide sequencing analysis was performed as the final result. The resulting modified strains were named 13032-thrABC, 13869-thrABC, and 14067-thrABC, representing the strains of ATCC13032, ATCC 13869, and ATCC 14067 carrying the pVWEx1-thrABC expression plasmid, respectively.
[0088] Example 6: lysC was introduced into 13032-thrABC, 13869-thrABC, and 14067-thrABC, respectively. T311I and hom G378E Competent cells of 13032-thrABC, 13869-thrABC, and 14067-thrABC were prepared and genetic recombination was performed according to the method in the C. glutamicum Handbook (Charpter 23).
[0089] The recombinant plasmid pK18mobsacB-speC-lysC was electroporated. T311I -1、pK18mobsacB-speC-lysC T311I -2 and pK18mobsacB-speC-lysC T311I -3 ITransformations were performed into 13032-thrABC, 13869-thrABC, and 14067-thrABC competent cells, respectively. Transformants were screened on BHI selective media containing 100 mg / L spectinomycin and 25 mg / L kanamycin. The selected transformants were cultured overnight in BHI liquid medium containing 25 mg / L kanamycin at 30°C with shaking at 200 rpm. During this culture, the transformants underwent a second recombination, removing the vector sequence from the genome through gene exchange and simultaneously introducing the target mutation. The cultures were serially diluted (to 10⁻⁶ ppm). -2 The diluted solution was spread onto BHI solid medium containing 10% sucrose and 25 mg / L kanamycin, and incubated at 30°C for 48 h. The resulting transformants should carry the target mutation and not the inserted vector sequence. The target sequence was amplified by PCR, and nucleotide sequencing analysis was performed as the final result. The resulting modified strains were named 13032-thrABC-C, 13869-thrABC-C, and 14067-thrABC-C, respectively, representing strains obtained by mutating the lysC gene in 13032-thrABC, 13869-thrABC, and 14067-thrABC, resulting in the T311I mutation in their encoded protein.
[0090] Following the methods outlined in the C. glutamicum Handbook (Charpter 23), competent cells of 13032-thrABC-C, 13869-thrABC-C, and 14067-thrABC-C were prepared and subjected to gene recombination.
[0091] The recombinant plasmid pK18mobsacB-speC-hom was electroporated. G378E -1、pK18mobsacB-speC-hom G378E -2 and pK18mobsacB-speC-hom G378E Transformations were performed on 13032-thrABC-C, 13869-thrABC-C, and 14067-thrABC-C competent cells, and transformants were screened on BHI selective media containing 100 mg / L spectinomycin and 25 mg / L kanamycin. The selected transformants were cultured overnight in BHI liquid medium containing 25 mg / L kanamycin at 30°C with shaking at 200 rpm. During this culture, a second recombination occurred in the transformants, removing the vector sequence from the genome through gene exchange and simultaneously introducing the target mutation. The cultures were serially diluted (to 10⁻⁶ ppm). -2The diluted solution was spread onto BHI solid medium containing 10% sucrose and 25 mg / L kanamycin, and incubated statically at 30°C for 48 h. The resulting transformants should carry the target mutation and not the inserted vector sequence. The target sequence was amplified by PCR, and nucleotide sequencing analysis was performed as the final result. The resulting modified strains were named SMCT301, SMCT302, and SMCT303, respectively. These strains were created by mutating the hom gene in strains 13032-thrABC-C, 13869-thrABC-C, and 14067-thrABC-C, resulting in the G378E mutation in the encoded protein.
[0092] Example 7: Shake-flask fermentation test of the fermentation performance of three model strains after the introduction of the threonine terminal pathway gene and the removal of threonine feedback inhibition. The culture medium used in the shake-flask fermentation test is as follows: Plate activation medium: BHI 37 g / L, 20 g / L agar powder.
[0093] Seed culture medium: peptone 5 g / L, yeast extract 5 g / L, sodium chloride 10 g / L, ammonium sulfate 16 g / L, urea 8 g / L, potassium dihydrogen phosphate 10.4 g / L, dipotassium hydrogen phosphate 21.4 g / L, biotin 5 mg / L, magnesium sulfate 3 g / L, glucose 50 g / L, pH 7.2.
[0094] Fermentation medium: corn steep liquor 50 mL / L, glucose 30 g / L, ammonium sulfate 4 g / L, MOPS 30 g / L, potassium dihydrogen phosphate 10 g / L, urea 20 g / L, biotin 10 mg / L, magnesium sulfate 6 g / L, ferrous sulfate 1 g / L, vitamin B1•HCl 40 mg / L, calcium pantothenate 50 mg / L, nicotinamide 40 mg / L, manganese sulfate 1 g / L, zinc sulfate 20 mg / L, copper sulfate 20 mg / L, pH 7.2.
[0095] The fermentation method is as follows: 1. Seed activation: Take the strain to be verified from the cryopreservation tube, streak it on seed activation medium, and incubate at 30℃ for 24h; 2. Seed culture: Pick 1 plate of activated seeds and transfer it to a 500 mL Erlenmeyer flask containing 30 mL of seed culture medium. Incubate at 30 °C and 230 r / min for 6-8 h with shaking. 3. Fermentation culture: Inoculate 6-8 mL of seed culture into a 500 mL Erlenmeyer flask containing 20 mL of fermentation medium, and culture at 30 °C and 150 r / min for 24 h with shaking. Perform 3 replicates for each strain.
[0096] 4. OD 562Measurement: The fermentation broth was diluted 100 times, and the absorbance was measured at a wavelength of 562 nm using a spectrophotometer. Each strain was tested in triplicate, and the average value was calculated. The results are shown in Table 2, where the data represents the average of the three parallel tests.
[0097] 5. Amino acid concentration determination: Centrifuge 2 mL of fermentation broth (12000 rpm, 2 min), collect the supernatant, and detect it using Agilent high-performance liquid chromatography (HPLC). Three replicates were performed for both the recombinant bacteria (test bacteria) and the control bacteria, and the average value was calculated. The results are shown in Table 2.
[0098] Table 2. Detection of amino acid yield in recombinant bacteria
[0099] The amino acid content in the fermentation broth was analyzed, and it was found that *Corynebacterium glutamicum* carrying the threonine terminal pathway gene and having its threonine terminal restriction removed significantly increased the threonine concentration. Specifically, SMCT301 showed a 240.8% increase in threonine production compared to the wild-type strain ATCC 13032 (from 2.5 g / L to 7.6 g / L); SMCT302 showed a 246.1% increase in threonine production compared to the wild-type strain ATCC 13869 (from 2.3 g / L to 7.1 g / L); and SMCT303 showed a 262.2% increase in threonine production compared to the wild-type strain ATCC 14067 (from 2.2 g / L to 7.0 g / L). These results indicate that the ability of the strains to produce threonine was significantly enhanced after the threonine terminal synthesis pathway was opened. Therefore, it can be demonstrated that SMCT301, SMCT302, and SMCT303, after metabolic engineering modification, became threonine-producing strains.
[0100] Example 8: The transcription factor mutant pcaR was introduced into the Corynebacterium glutamicum model strain ATCC 13032 and the threonine-producing strain SMCT301, respectively. A193T -1, pcaR A193S -1 Competent cells of the C. glutamicum model strain ATCC 13032 and the threonine-producing strain SMCT301 were prepared and recombined according to the method in the C. glutamicum Handbook (Charpter 23).
[0101] The recombination method is the same as in Example 6, that is, the recombinant plasmid pK18mobsacB-speC-pcaR is recombined by electroporation. A193T -1 and pK18mobsacB-speC-pcaR A193STransformations were performed on ATCC 13032 and SMCT301 competent cells, respectively, and transformants were screened on BHI selective media containing 100 mg / L spectinomycin and 25 mg / L kanamycin. The selected transformants were cultured overnight in BHI liquid medium containing 25 mg / L kanamycin at 30°C with shaking at 200 rpm. During this culture, the transformants underwent a second recombination, removing the vector sequence from the genome through gene exchange and simultaneously introducing the target mutation. The cultures were serially diluted (to 10⁻⁶ oz) to different concentrations. -2 The diluted solution was spread onto BHI solid medium containing 10% sucrose and 25 mg / L kanamycin, and incubated at 30°C for 48 h. The resulting transformants should carry the target mutation and not the inserted vector sequence. The target sequence was amplified by PCR, and nucleotide sequencing analysis was performed as the final result. The final result was a transcription factor mutant pcaR expressed by the ATCC 13032 strain. A193T The target modified strain, named SMCT481, expressed the transcription factor mutant pcaR. A193S The target strain was named SMCT482; a transcription factor mutant pcaR was obtained from the starting strain SMCT301. A193T The target modified strain, named SMCT487, expressed the transcription factor mutant pcaR. A193S The modified strain with the target strain was named SMCT488.
[0102] Example 9: The transcription factor mutant pcaR was introduced into the Corynebacterium glutamicum model strain ATCC 13869 and the threonine-producing strain SMCT302, respectively. A193T -2, pcaR A193S -2 Competent cells of the C. glutamicum model strain ATCC 13869 and the threonine-producing strain SMCT302 were prepared and recombined according to the method in the C. glutamicum Handbook (Charpter 23).
[0103] The recombination method is the same as in Example 6, that is, the recombinant plasmid pK18mobsacB-speC-pcaR is recombined by electroporation. A193T -2 and pK18mobsacB-speC-pcaR A193STransformations were performed on ATCC 13869 and SMCT302 competent cells, respectively, and transformants were screened on BHI selective media containing 100 mg / L spectinomycin and 25 mg / L kanamycin. The selected transformants were cultured overnight in BHI liquid medium containing 25 mg / L kanamycin at 30°C with shaking at 200 rpm. During this culture, a second recombination occurred in the transformants, removing the vector sequence from the genome through gene exchange and simultaneously introducing the target mutation. The cultures were serially diluted (to 10⁻⁶ ppm). -2 The diluted solution was spread onto BHI solid medium containing 10% sucrose and 25 mg / L kanamycin, and incubated at 30°C for 48 h. The resulting transformants should carry the target mutation and not the inserted vector sequence. The target sequence was amplified by PCR, and nucleotide sequencing analysis was performed as the final result. The final result was the transcription factor mutant pcaR expressed by the ATCC 13869 strain. A193T The target modified strain, named SMCT483, expressed the transcription factor mutant pcaR. A193S The target strain was named SMCT484; a transcription factor mutant pcaR was obtained from the starting strain SMCT302. A193T The target modified strain, named SMCT489, expressed the transcription factor mutant pcaR. A193S The modified strain was named SMCT490.
[0104] Example 10: The transcription factor mutant pcaR was introduced into the Corynebacterium glutamicum model strain ATCC 14067 and the threonine-producing strain SMCT303, respectively. A193T -3, pcaR A193S -3 Competent cells of the C. glutamicum model strain ATCC 14067 and the threonine-producing strain SMCT303 were prepared and recombined according to the method in the C. glutamicum Handbook (Charpter 23).
[0105] The recombination method is the same as in Example 6, that is, the recombinant plasmid pK18mobsacB-speC-pcaR is recombined by electroporation. A193T -3 and pK18mobsacB-speC-pcaR A193STransformations were performed on ATCC 14067 and SMCT303 competent cells, respectively, and transformants were screened on BHI selective media containing 100 mg / L spectinomycin and 25 mg / L kanamycin. The selected transformants were cultured overnight in BHI liquid medium containing 25 mg / L kanamycin at 30°C with shaking at 200 rpm. During this culture, the transformants underwent a second recombination, removing the vector sequence from the genome through gene exchange and simultaneously introducing the target mutation. The cultures were serially diluted (to 10⁻⁶ ppm). -2 The diluted solution was spread onto BHI solid medium containing 10% sucrose and 25 mg / L kanamycin, and incubated at 30°C for 48 h. The resulting transformants should carry the target mutation and not the inserted vector sequence. The target sequence was amplified by PCR, and nucleotide sequencing analysis was performed as the final result. The final result was a transcription factor mutant pcaR expressed by the ATCC 14067 strain. A193T The target strain, named SMCT485, was modified to express the transcription factor mutant pcaR. A193S The target strain was named SMCT486; a transcription factor mutant pcaR was obtained from the starting strain SMCT303. A193T The target modified strain, named SMCT491, expressed the transcription factor mutant pcaR. A193S The modified strain with -3 was named SMCT492.
[0106] Example 11: Shake-flask fermentation test of the fermentation performance of three wild-type strains and three threonine-producing strains after the introduction of transcription factor mutants. The culture medium and fermentation method used in the shake-flask fermentation test were the same as in Example 7, as detailed below: Plate activation medium: BHI 37 g / L, 20 g / L agar powder.
[0107] Seed culture medium: peptone 5 g / L, yeast extract 5 g / L, sodium chloride 10 g / L, ammonium sulfate 16 g / L, urea 8 g / L, potassium dihydrogen phosphate 10.4 g / L, dipotassium hydrogen phosphate 21.4 g / L, biotin 5 mg / L, magnesium sulfate 3 g / L, glucose 50 g / L, pH 7.2.
[0108] Fermentation medium: corn steep liquor 50 mL / L, glucose 30 g / L, ammonium sulfate 4 g / L, MOPS 30 g / L, potassium dihydrogen phosphate 10 g / L, urea 20 g / L, biotin 10 mg / L, magnesium sulfate 6 g / L, ferrous sulfate 1 g / L, vitamin B1•HCl 40 mg / L, calcium pantothenate 50 mg / L, nicotinamide 40 mg / L, manganese sulfate 1 g / L, zinc sulfate 20 mg / L, copper sulfate 20 mg / L, pH 7.2.
[0109] The fermentation method is as follows: 1. Seed activation: Take the strain to be verified from the cryopreservation tube, streak it on seed activation medium, and incubate at 30℃ for 24h; 2. Seed culture: Pick 1 plate of activated seeds and transfer it to a 500 mL Erlenmeyer flask containing 30 mL of seed culture medium. Incubate at 30 °C and 230 r / min for 6-8 h with shaking. 3. Fermentation culture: Inoculate 6-8 mL of seed culture into a 500 mL Erlenmeyer flask containing 20 mL of fermentation medium, and culture at 30 °C and 150 r / min for 24 h with shaking. Perform 3 replicates for each strain.
[0110] 4. OD 562 Measurement: The fermentation broth was diluted 100 times, and the absorbance was measured at a wavelength of 562 nm using a spectrophotometer. Three replicates were performed for each strain, and the average value was calculated. The results are shown in Table 3, where the data represents the average of the three replicates.
[0111] 5. Amino acid concentration determination: Centrifuge 2 mL of fermentation broth (12000 rpm, 2 min), collect the supernatant, and detect it using Agilent high-performance liquid chromatography (HPLC). Three replicates were performed for both the recombinant bacteria (test bacteria) and the control bacteria, and the average value was calculated. The results are shown in Table 3.
[0112] Table 3. Detection of amino acid yield in recombinant bacteria
[0113] Note: The P-value after threonine production (g / L) is the P-value for analyzing the significant difference in threonine production between each test strain and its corresponding control strain; the P-value after conversion rate (%) is the P-value for analyzing the significant difference in conversion rate between each test strain and its corresponding control strain.
[0114] Analysis of the amino acid content in the fermentation broth revealed the presence of a mutated transcription factor pcaR. A193T and pcaR A193SThe threonine concentration in the culture medium of Corynebacterium glutamicum was increased to varying degrees, suggesting an improved efficiency in threonine synthesis or secretion, which is attributed to a mutated transcription factor. Among different threonine-producing bacteria, those carrying the mutant pcaR... A193T The modified bacteria showed a more significant increase in threonine production and yield.
[0115] In summary, the mutant transcription factor provided by this invention promotes the production and yield of threonine in Corynebacterium. The mutant transcription factor is more conducive to the synthesis of threonine or promotes its secretion into the extracellular space. Furthermore, the mutant transcription factor of this invention has universality and can improve the synthesis efficiency of different strains and various amino acids.
[0116] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. An engineered bacterium, characterized in that, The engineered bacteria express a mutated transcription factor or contain a nucleic acid molecule encoding the mutated transcription factor. The mutated transcriptional regulator, compared with the wild-type transcriptional regulator PcaR of Corynebacterium glutamicum, contains a mutation at amino acid position 193, which is either threonine or serine.
2. The engineered bacteria according to claim 1, characterized in that, The mutated transcriptional regulator, compared with the wild-type transcriptional regulator PcaR of Corynebacterium glutamicum, contains a mutation at position 193 where alanine is mutated to threonine or serine. The wild-type transcriptional regulatory factor PcaR of Corynebacterium glutamicum has an amino acid sequence as shown in SEQ ID NO.5, 7 or 9; Preferably, the amino acid sequence of the mutated transcriptional regulator is any one of the following (1)-(3): (1) The amino acid sequence obtained by mutating alanine at position 193 of the sequence shown in SEQ ID NO.5 to threonine or serine; (2) The amino acid sequence obtained by mutating alanine at position 193 of the sequence shown in SEQ ID NO.7 to threonine or serine; (3) The amino acid sequence obtained by mutating alanine at position 193 of the sequence shown in SEQ ID NO.9 to threonine or serine; Preferably, the engineered bacteria are Corynebacterium or Escherichia.
3. The engineered bacteria according to claim 1 or 2, characterized in that, The engineered bacteria are able to accumulate amino acids, and their threonine production and / or conversion rate are increased by expressing mutated transcription factors or containing nucleic acid molecules encoding said mutated transcription factors.
4. A method for producing amino acids or their derivatives, characterized in that, The method includes: culturing the engineered bacteria according to any one of claims 1 to 3, and collecting the amino acid or its derivative from the culture; Preferably, the amino acid is threonine.
5. A mutated transcriptional regulator, characterized in that, The mutated transcriptional regulator, compared to the wild-type transcriptional regulator PcaR of Corynebacterium glutamicum, contains a mutation at amino acid position 193, which is either threonine or serine.
6. The mutated transcription regulator according to claim 5, characterized in that, The mutated transcriptional regulator, compared with the wild-type transcriptional regulator PcaR of Corynebacterium glutamicum, contains a mutation at position 193 where alanine is mutated to threonine or serine. The wild-type transcriptional regulatory factor PcaR of Corynebacterium glutamicum has an amino acid sequence as shown in SEQ ID NO.5, 7 or 9; Preferably, the amino acid sequence of the mutated transcriptional regulator is any one of the following (1)-(3): (1) The amino acid sequence obtained by mutating alanine at position 193 of the sequence shown in SEQ ID NO.5 to threonine or serine; (2) The amino acid sequence obtained by mutating alanine at position 193 of the sequence shown in SEQ ID NO.7 to threonine or serine; (3) The amino acid sequence obtained by mutating alanine at position 193 of the sequence shown in SEQ ID NO.9 to threonine or serine.
7. A biomaterial, characterized in that, The biomaterial includes any one of the following: (1) A nucleic acid molecule encoding the mutated transcriptional regulatory factor as described in claim 5 or 6; (2) An expression cassette containing the nucleic acid molecule described in (1); (3) A vector comprising the nucleic acid molecule described in (1) or the expression cassette described in (2); (4) A host cell containing the nucleic acid molecule described in (1) or the expression cassette described in (2) or the vector described in (3).
8. Any of the following applications of the transcriptional regulatory factor PcaR, or the mutated transcriptional regulatory factor of claim 5 or 6, or the biological material of claim 7: (1) Application in regulating the production capacity of bacterial amino acids or their derivatives; (2) Application in the construction of bacteria for the production of amino acids or their derivatives; (3) Applications in the production of amino acids or their derivatives; (4) Application in increasing the yield and / or conversion rate of bacterial amino acids or their derivatives; (5) Its application as a marker in screening bacteria for amino acid production; Preferably, the amino acid is threonine, and / or the bacteria are Corynebacterium or Escherichia, and / or the transcriptional regulatory factor PcaR has an amino acid sequence as shown in SEQ ID NO. 5, 7 or 9.
9. A method for regulating the production capacity of amino acids or their derivatives by bacteria, characterized in that, The method includes regulating the gene of the bacterial transcriptional regulatory factor PcaR.
10. The method according to claim 9, characterized in that, The bacteria are either Corynebacterium or Escherichia; Preferably, the amino acid is threonine.
